The use of chemical permeation enhancers (PEs) is the most widely tested approach to
improve oral absorption of low permeability active agents, as represented by peptides …

Introduction The FDA approval of oral semaglutide for type 2 diabetes (2019) and oral
octreotide for acromegaly (2020) is evidence that selected niche peptides can be …

Surfactants are a diverse group of compounds that share the capacity to adsorb at the
boundary between distinct phases of matter. They are used as pharmaceutical excipients …

We review the use of molecular dynamics (MD) simulation as a drug design tool in the
context of the role that the lipid membrane can play in drug action, ie, the interaction …

Recently, two oral-administered peptide pharmaceuticals, semaglutide and octreotide, have
been developed and are considered as a breakthrough in peptide and protein drug delivery …

The delivery of proteins and peptides via an oral route poses numerous challenges to
improve the oral bioavailability and patient compliance. To overcome these challenges, as …

This paper reviews many of the properties of a peptide that need to be considered prior to
development as an oral dosage form when co-formulated with a permeation enhancer to …

In this work, we set out to better understand how the permeation enhancer sodium caprate
(C10) influences the intestinal absorption of macromolecules. FITC-dextran 4000 (FD4) was …

SNAC and C 10 are intestinal permeation enhancers (PEs) used in formulations of peptides
for oral delivery in clinical trials. Our aims were to compare their:(i) mechanism of action in …

Sodium caprate (C10) has been widely evaluated as an intestinal permeation enhancer for
the oral delivery of macromolecules. However, the effect of C10 on the intestinal absorption …